Garsorasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer: Updated Results from a Phase 2 Study

被引：0

作者：

Li, Z. ^{[1
]}

Lu, S. ^{[1
]}

Dang, X. ^{[2
]}

Huang, D. ^{[3
]}

Jin, S. ^{[4
,5
]}

Li, W. ^{[6
]}

Shi, J. ^{[7
]}

Wang, X. ^{[8
,21
]}

Zhang, Y. ^{[9
]}

Song, Z. ^{[9
]}

Zhang, J. ^{[10
]}

Zhuang, W. ^{[11
]}

Liu, X. ^{[12
]}

Jiang, L. ^{[1
]}

Meng, X. ^{[13
]}

Zhao, M. ^{[14
]}

Zhou, J. ^{[15
]}

Zhang, L. ^{[16
,44
]}

Wang, P. ^{[17
]}

Luo, H. ^{[18
]}

Yang, J. ^{[19
]}

Cang, S. ^{[20
]}

Wang, X. ^{[8
,21
]}

Wang, J. ^{[22
]}

Cui, J. ^{[23
]}

Yu, Y. ^{[24
]}

Zhang, Z. ^{[25
]}

Lu, J. ^{[26
]}

Yang, W. ^{[27
]}

Li, G. ^{[28
]}

Feng, J. ^{[29
]}

Lv, D. ^{[30
]}

Wu, L. ^{[31
]}

Fang, Y. ^{[32
]}

Wang, Y. ^{[33
]}

Zhao, Y. ^{[34
]}

Cao, B. ^{[35
]}

Zhu, W. ^{[36
]}

Zhuang, Z. ^{[37
]}

Li, Q. ^{[38
]}

Wang, M. ^{[39
]}

Zhou, H. ^{[39
]}

Dong, X. ^{[40
]}

Hu, S. ^{[41
]}

Fang, J. ^{[42
]}

Xu, C. -W. ^{[43
]}

Wang, W. ^{[44
]}

Xiang, Z. ^{[44
]}

Shi, Z. ^{[44
]}

Zhang, L. ^{[16
,44
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China

[3] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Shenzhen, Peoples R China

[5] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China

[6] Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China

[7] Linyi Canc Hosp, Linyi, Shandong, Peoples R China

[8] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Guangzhou, Peoples R China

[9] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China

[10] Shanxi Med Univ, Affiliated Bethune Hosp, Taiyuan, Peoples R China

[11] Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[12] Cent South Univ, Xiangya Hosp 3, Changsha, Peoples R China

[13] Shandong Canc Hosp, Jinan, Peoples R China

[14] China Med Univ, Hosp 1, Shenyang, Peoples R China

[15] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[16] Yantai Yuhuangding Hosp, Yantai, Peoples R China

[17] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China

[18] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China

[19] Tangshan Canc Hosp, Tangshan, Peoples R China

[20] Henan Prov Peoples Hosp, Zhengzhou, Peoples R China

[21] Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China

[22] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China

[23] First Hosp Jilin Univ, Changchun, Peoples R China

[24] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China

[25] Anhui Prov Canc Hosp, Hefei, Peoples R China

[26] Nantong Tumor Hosp, Nantong, Peoples R China

[27] Shanxi Canc Hosp, Taiyuan, Peoples R China

[28] Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China

[29] Jiangsu Canc Hosp, Nanjing, Peoples R China

[30] Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China

[31] Hunan Canc Hosp, Changsha, Peoples R China

[32] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China

[33] Ningxia Med Univ, Gen Hosp, Yinchuan, Ningxia, Peoples R China

[34] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[35] Peking Univ Third Hosp, Beijing, Peoples R China

[36] Baotou Cent Hosp, Baotou, Peoples R China

[37] Soochow Univ, Affiliated Hosp 2, Suzhou, Peoples R China

[38] Chengde Med Univ, Affiliated Hosp, Chengde, Peoples R China

[39] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China

[40] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[41] Hubei Canc Hosp, Wuhan, Peoples R China

[42] Beijing Canc Hosp, Beijing, Peoples R China

[43] Nanjing Univ, Sch Med, Jinling Hosp, Nanjing, Peoples R China

[44] InventisBio Co Ltd, Shanghai, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

Non-small-cell; Lung Cancer; KRAS G12C mutation; Phase; 2; study;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA14.03

引用

页码：S40 / S41

页数：2

共 50 条

[1] Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer
Li, Ziming
Dang, Xiaomin
Huang, Dingzhi
Jin, Shi
Li, Weiwei
Shi, Jianhua
Wang, Xicheng
Zhang, Yiping
Song, Zhengbo
Zhang, Junping
Zhuang, Wu
Liu, Xuewen
Jiang, Liyan
Meng, Xiangjiao
Zhao, Mingfang
Zhou, Jianying
Zhang, Liangming
Wang, Pingli
Luo, Hui
Yang, Junquan
Cang, Shundong
Wang, Xiang
Wang, Jing
Cui, Jiuwei
Yu, Yan
Zhang, Zhihong
Lu, Junguo
Yang, Weihua
Li, Gaofeng
Feng, Jifeng
Lv, Dongqing
Wu, Lin
Fang, Yong
Wang, Yan
Zhao, Yanqiu
Cao, Baoshan
Zhu, Wei
Zhuang, Zhixiang
Li, Qingshan
Wang, Mingxi
Zhou, Huan
Dong, Xiaorong
Hu, Sheng
Fang, Jian
Zhang, Yihong
Wang, Wenjia
Xiang, Ziyong
Shi, Zhe
Zhang, Ling
Lu, Shun
CANCER RESEARCH, 2024, 84 (07)
[2] How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Ricciuti, Biagio
Mira, Alessia
Andrini, Elisa
Scaparone, Pietro
Michelina, Sandra Vietti
Pecci, Federica
Cantini, Luca
De Giglio, Andrea
Lamberti, Giuseppe
Ambrogio, Chiara
Metro, Giulio
DRUGS IN CONTEXT, 2022, 11
[3] Sotorasib in KRAS G12C-mutated non-small cell lung carcinoma
Lorenz, Judith
PNEUMOLOGIE, 2023, 77 (11): : 846 - 846
[4] Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
de Langen, Adrianus Johannes
Johnson, Melissa L.
Mazieres, Julien
Dingemans, Anne-Marie C.
Mountzios, Giannis
Pless, Miklos
Wolf, Juergen
Schuler, Martin
Lena, Herve
Skoulidis, Ferdinandos
Yoneshima, Yasuto
Kim, Sang-We
Linardou, Helena
Novello, Silvia
van der Wekken, Anthonie J.
Chen, Yuanbin
Peters, Solange
Felip, Enriqueta
Solomon, Benjamin J.
Ramalingam, Suresh S.
Dooms, Christophe
Lindsay, Colin R.
Ferreira, Carlos Gil
Blais, Normand
Obiozor, Cynthia C.
Wang, Yang
Mehta, Bhakti
Varrieur, Tracy
Ngarmchamnanrith, Gataree
Stollenwerk, Bjoern
Waterhouse, David
Paz-Ares, Luis
FUTURE ONCOLOGY, 2025,
[5] Garsorasib in patients with KRAS G 12 C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
Li, Ziming
Dang, Xiaomin
Huang, Dingzhi
Jin, Shi
Li, Weiwei
Shi, Jianhua
Wang, Xicheng
Zhang, Yiping
Song, Zhengbo
Zhang, Junping
Zhuang, Wu
Liu, Xuewen
Jiang, Liyan
Meng, Xiangjiao
Zhao, Mingfang
Zhou, Jianying
Zhang, Liangming
Wang, Pingli
Luo, Hui
Yang, Junquan
Cang, Shundong
Wang, Xiang
Zhang, Ling
Lu, Shun
LANCET RESPIRATORY MEDICINE, 2024, 12 (08): : 589 - 598
[6] Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary
Dy, Grace K.
Govindan, Ramaswamy
Velcheti, Vamsidhar
Falchook, Gerald S.
Italiano, Antoine
Wolf, Juergen
Sacher, Adrian G.
Takahashi, Toshiaki
Ramalingam, Suresh S.
Dooms, Christophe
Kim, Dong-Wan
Addeo, Alfredo
Desai, Jayesh
Schuler, Martin
Tomasini, Pascale
Hong, David S.
Lito, Piro
Tran, Qui
Jones, Simon
Anderson, Abraham
Hindoyan, Antreas
Snyder, Wendy
Skoulidis, Ferdinandos
Li, Bob T.
FUTURE ONCOLOGY, 2024, 20 (03) : 113 - 120
[7] Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer
Jing, Yawan
Cheng, Ruixin
Zeng, Hao
Huang, Qin
He, Dongyu
Sun, Jiayi
Tian, Panwen
Li, Yalun
INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17 : 4507 - 4517
[8] Early-stage KRAS G12C-mutated non-small cell lung cancer (NSCLC) in Australia.
Mitchell, Paul
Dharmaraj, Devisri
Knight, Simon
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital
Bessy, C.
Blin, T.
Pichon, E.
Marchand-Adam, S.
Carmier, D.
REVUE DES MALADIES RESPIRATOIRES, 2023, 40 (01) : 17 - 23
[10] Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer
Milner-Watts, Charlotte
O'Sullivan, Hazel
Stewart, James
Idaikkadar, Praveena
Tokaca, Nadza
Davidson, Michael
Yousaf, Nadia
Bhosle, Jaishree
Popat, Sanjay
O'Brien, Mary
Minchom, Anna
LUNG CANCER, 2023, 178 : S31 - S32

← 1 2 3 4 5 →